# Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

> **NCT01616459** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 953 (actual)

## Conditions studied

- Infections, Streptococcal

## Interventions

- **BIOLOGICAL:** Pneumococcal conjugate vaccine GSK2830929A
- **BIOLOGICAL:** Pneumococcal conjugate vaccine GSK2830930A
- **BIOLOGICAL:** Synflorix™
- **BIOLOGICAL:** Prevnar 13™
- **BIOLOGICAL:** Infanrix hexa™

## Key facts

- **NCT ID:** NCT01616459
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-11
- **Primary completion:** 2013-04-25
- **Final completion:** 2014-01-22
- **Target enrollment:** 953 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01616459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01616459, "Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01616459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*